Both DPP-4 inhibitors and GLP-1 RAs are effective at lowering hemoglobin A1c levels. Incretin-based therapies have a low incidence of hypoglycemia and are safe to use in patients with chronic kidney disease. In addition, studies have suggested that DDP-4 inhibitors may reduce albuminuria and improve various renal inflammatory markers. However, GLP-1 RAs and sodium-glucose cotransporter 2 (SGLT2) inhibitors more effectively lower glycemia compared with DPP-4 inhibitors.
GLP-1 RAs have been shown to lower all-cause mortality and nonfatal cardiovascular complications. Although DDP-4 inhibitors may be safe to use in patients with heart failure, they are not effective in reducing cardiovascular outcomes.
Learn more about type 2 diabetes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori, Anne L. Peters. Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy - Medscape - May 16, 2022.